NSE: ERIS | BSE: 540596

Mid-range Performer

Download real time

1581.50 -13.90 (-0.87%)

44.14% Gain from 52W Low

34,467 NSE+BSE Volume

NSE 01 Dec, 2025 3:31 PM (IST)

21,542.7

Market Cap

High in industry

Beta 1Year

Very Low volatility

Eris Lifesciences Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ERIS, BSE:540596 Eris Lifesciences Ltd.

Search Inside the pdf :

Eris Lifesciences Ltd.

12 Nov 2025

1581.50

-0.87%

Steady execution in DF drives earnings

Neutral: Eris Lifesciences Ltd.

Target

Motilal Oswal

Eris Lifesciences (ERIS) reported in-line revenue/EBITDA for the quarter. However, there was a slight miss on earnings due to higher interest costs and tax rate for the quarter.

Motilal Oswal increased Neutral price target of Eris Lifesciences Ltd. to 1530.0 on 12 Nov, 2025.

Eris Lifesciences Ltd.

06 Aug 2025

1581.50

-0.87%

Eris Lifesciences (ERIS IN) Q1FY26 Result Update Revenue...

Buy: Eris Lifesciences Ltd.

Target

Prabhudas Lilladhar

Eris Lifesciences' (ERIS) Q1FY26 EBITDA was broadly in line with our estimate (Rs2.75bn; up 11% YoY). Though Q1FY26 revenue growth (up 7.4% YoY) was muted, we see pick up in coming quarters as insulin shortages stabilize, export pick up and likely additional market share gain from human insulin market. Eris has opted for inorganic route to diversify and scale up existing portfolio. This has been implemented without diluting margins. We expect margins to scale up from the current level of 35% in FY25 as revenue scales up from recent...

Promoters unpledged 0.01% of shares in last quarter. Total pledge stands at 16.92% of promoter holdings

Eris Lifesciences Ltd.

20 May 2025

1581.50

-0.87%

Eris Lifesciences (ERIS IN) Q4FY25 Result Update Multiple...

Buy: Eris Lifesciences Ltd.

Target

Prabhudas Lilladhar

Strong FY26 guidance with +15% revenue growth with 36% OPM. up 70% YoY). Eris has opted for inorganic route to diversify and scale up expect margins to scale up from the current level of 35% as revenue scales up from recent acquisitions, which are currently operating at sub-optimal profitability. The company has multiple growth levers such as broad-based...

Eris Lifesciences Ltd. is trading below its 30 day SMA of 1603.2

Eris Lifesciences Ltd.

19 May 2025

1581.50

-0.87%

Lower-than-est. 4Q due to supply disruption for select products

Neutral: Eris Lifesciences Ltd.

Target

Motilal Oswal

Eris Lifesciences (ERIS) posted lower-than-expected 4QFY25 performance. This has been largely due to a marginal slip in the execution, particularly in the insulin revenue.

Eris Lifesciences Ltd. has an average target of 1641.00 from 3 brokers.

Eris Lifesciences Ltd.

05 Feb 2025

1581.50

-0.87%

Eris Lifesciences (BUY): First player to launch GLP products in India

Buy: Eris Lifesciences Ltd.

Target

BOB Capital Markets Ltd.

Base domestic growth at 12% vs IMP growth of 8% due to new product launches and price increase

Motilal Oswal increased Neutral price target of Eris Lifesciences Ltd. to 1530.0 on 12 Nov, 2025.

Eris Lifesciences Ltd.

05 Feb 2025

1581.50

-0.87%